Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Teradyne, Inc. — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.08 (market cap $2.86B), while Teradyne, Inc. trades at $355.91 (market cap $59.45B). The key difference: Teradyne, Inc. is far larger — about 20.8× Dyne Therapeutics Inc. Common Stock's market cap, and Teradyne, Inc. pays a 0.14% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Teradyne, Inc. for 37 Days on average.
| DYN | TER | |
|---|---|---|
Market Cap | $2.86B | $59.45B |
Volume | 3,341,579 | 2,735,541 |
Sector | Health | Technology |
52-Week High | $26.78 | $483.84 |
52-Week Low | $14.60 | $138.09 |
Typical Hold Time | 0 Days | 37 Days |
Enterprise Value | $2.18B | $59.20B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Teradyne (TER) trades at $359.44, down 6.36% over 24 hours, reflecting recent bearish technical signals. The stock shows strong fundamentals with a 25.77% net income margin and consistent earnings beats in recent quarters. Recent news highlights expansion in AI-driven test equipment, including the Magnum E2 and Iris 100 platforms, targeting growth in semiconductor and data center markets. Analyst consensus remains bullish with a $461.50 price target, though technical indicators suggest near-term caution.
Outlook is positive due to robust profitability and AI-related demand, but risks include competitive pressures and market volatility. The stock offers growth potential if execution aligns with analyst expectations, though investors should monitor earnings consistency and industry trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
